Volume 17, Number 6—June 2011
Dispatch
Salmonella enterica Serotype Typhi with Nonclassical Quinolone Resistance Phenotype
Table 1
Subpopulation |
No. isolates |
Nal MICs,† μg/mL | Cip MICs,† μg/mL | QRDR mutation (no./no. tested) |
|||||
---|---|---|---|---|---|---|---|---|---|
MIC50 |
MIC90 |
Range |
MIC50 |
MIC90 |
Range |
||||
A | 554 | 4 | 4 | 1–8 | 0.008 | 0.025 | 0.002–0.08 | WT (75/77) | |
gyrB Leu465 (2/77) | |||||||||
C | 119 | >256 | >256 | 128–>256 | 0.25 | 0.5 | 0.06–0.5 | gyrA Phe83 (24/44) | |
gyrA Tyr83 (12/44) | |||||||||
gyrA Asn87 (4/44) | |||||||||
gyrA Gly87 (2/44) | |||||||||
gyrA Phe83 and parE Asn420 (2/44) | |||||||||
D | 1 | >256 | 8 | gyrA Phe83, gyrA Asn87, and parC Ile80 |
*Nal, nalidixic acid; Cip, ciprofloxacin; QRDR, quinolone resistance–determining region of the gyrA, gyrB, parC, and parE genes; WT, wild type.
†MICs of Nal and Cip were determined by Etest strips. MIC50, 50% below; MIC90, 90% below.
.
Page created: August 03, 2011
Page updated: August 03, 2011
Page reviewed: August 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.